{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:16:09Z","timestamp":1788934569454,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01287-9","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T12:50:56Z","timestamp":1755348656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-7310","authenticated-orcid":false,"given":"Arif Mohammed","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshi Krishna","family":"Muddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Avinash","family":"Bonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraja","family":"Siripurapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Takreem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Sana","family":"Shahnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sannapaneni","family":"Krishnaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Nageshwar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","unstructured":"Siegel et al. Cancer statistics, 2025. 2025.https:\/\/doi.org\/10.3322\/caac.21871.","DOI":"10.3322\/caac.21871"},{"issue":"3","key":"1287_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"1287_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(20)30974-0.","journal-title":"Lancet"},{"issue":"19","key":"1287_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"1287_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"4","key":"1287_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/jcpt.13341","volume":"46","author":"X Dong","year":"2021","unstructured":"Dong X, Zhao X, Li Y, et al. Meta analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab paclitaxel as first line treatment for metastatic pancreatic cancer. J Clin Pharm Ther. 2021;46(4):998\u20131007. https:\/\/doi.org\/10.1111\/jcpt.13341.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"1287_CR7","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1007\/s15010-019-01310-3","volume":"42","author":"O Looseveld","year":"2019","unstructured":"Looseveld O, Pailaud E, Greillier L, et al. Comaparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer: a metanalysis of real world evidence. Infect Dis (Lond). 2019;42(12):6063\u201370. https:\/\/doi.org\/10.1007\/s15010-019-01310-3.","journal-title":"Infect Dis (Lond)."},{"issue":"4","key":"1287_CR8","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology \u2013 a primer. Am J Cancer Res. 2021;11(4):1121\u201331.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"1287_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.14740\/wjon1604","volume":"14","author":"N Merza","year":"2023","unstructured":"Merza N, Farooqui SK, Dar SH, et al. FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel as first-line treatment for pancreatic cancer: a systematic review and meta-analysis. World J Oncol. 2023;14(5):325\u201339. https:\/\/doi.org\/10.14740\/wjon1604.","journal-title":"World J Oncol"},{"issue":"10409","key":"1287_CR10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(23)01366-1.","journal-title":"Lancet"},{"issue":"1","key":"1287_CR11","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with Nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(1):e2350756. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50756.","journal-title":"JAMA Netw Open"},{"issue":"suppl2","key":"1287_CR12","doi-asserted-by":"publisher","first-page":"S923","DOI":"10.1016\/annonc\/annonc1605","volume":"35","author":"S Kobayashi","year":"2024","unstructured":"Kobayashi S, Ohba A, Ozaka M, et al. GnP vs. mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611) trial. Ann Oncol. 2024;35(suppl2):S923\u201336. https:\/\/doi.org\/10.1016\/annonc\/annonc1605.","journal-title":"Ann Oncol"},{"issue":"8","key":"1287_CR13","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782\u201394. https:\/\/doi.org\/10.1093\/jnci\/djz073.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1287_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41416-021-01308-9","volume":"124","author":"E Auclin","year":"2021","unstructured":"Auclin E, Bournet B, Hervieu V, et al. Role of FOLFIRINOX and chemoradiotherapy in locally advanced pancreatic adenocarcinoma: update of the AGEO cohort. Br J Cancer. 2021;124(11):1941\u20138. https:\/\/doi.org\/10.1038\/s41416-021-01308-9.","journal-title":"Br J Cancer."},{"issue":"17","key":"1287_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844\u201353. https:\/\/doi.org\/10.1001\/jama.2016.4324.","journal-title":"JAMA"},{"issue":"11","key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1287_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer DH, Cicconi S, et al. Immediate surgery compared with neoadjuvant gemcitabine-based chemotherapies or chemoradiotherapy in borderline resectable pancreatic cancer (ESPAC-5 trial): A four-arm, multicentre, randomized phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(22)00348-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"EM O'Reilly","year":"2022","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable pancreatic adenocarcinoma: The Alliance A021501 phase 2 randomized clinical trial. JAMAOncol. 2022;8(9):1263\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2319.","journal-title":"JAMAOncol"},{"issue":"4","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/SLA.0000000000003031","volume":"271","author":"S Tsai","year":"2020","unstructured":"Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19\u20139 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271(4):740\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000003031.","journal-title":"Ann Surg."},{"issue":"6","key":"1287_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00280-020-04165-2","volume":"86","author":"C Ye","year":"2020","unstructured":"Ye C, Sadula A, Ren S, et al. The prognostic value of CA19\u20139 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol. 2020;86(6):731\u201340. https:\/\/doi.org\/10.1007\/s00280-020-04165-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1287_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/jcm9051477","volume":"9","author":"W Lee","year":"2020","unstructured":"Lee W, Lee HW, Lee JH, et al. Reduced and normalized carbohydrate antigen 19\u20139 concentrations after neoadjuvant chemotherapy have comparable prognostic performance in patients with borderline resectable and locally advanced pancreatic cancer. J Clin Med. 2020;9(5):1477. https:\/\/doi.org\/10.3390\/jcm9051477.","journal-title":"J Clin Med."},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"153303382110430","DOI":"10.1177\/15330338211043030","volume":"20","author":"YM Kang","year":"2021","unstructured":"Kang YM, Wang H, Li R, Pan G. Prognostic role of carbohydrate antigen 19\u20139 in predicting survival of patients with pancreatic cancer: a meta-analysis. Technol Cancer Res Treat. 2021;20:15330338211043030. https:\/\/doi.org\/10.1177\/15330338211043030.","journal-title":"Technol Cancer Res Treat."},{"key":"1287_CR23","doi-asserted-by":"publisher","unstructured":"Long AM, Amparo A, Goodhart A, Ahmad A, Waters AM. Evaluation of KRAS inhibitor\u2011directed therapies for pancreatic ductal adenocarcinoma. Therapeutic Adv Med Oncol 2024;November 7. https:\/\/doi.org\/10.1177\/1758835924123456.","DOI":"10.1177\/1758835924123456"},{"issue":"5","key":"1287_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","volume":"32","author":"S Stickler","year":"2024","unstructured":"Stickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer. Oncol Res. 2024;32(5):799\u2013805. https:\/\/doi.org\/10.32604\/or.2024.045356.","journal-title":"Oncol Res"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01287-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T01:02:25Z","timestamp":1755392545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01287-9","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"14 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Waiver was given as it is retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The Institutional Review Board of Asian institute of gastroenterology provided approval for this study (IRB No. AIG\/IEC-Post BH &R 56\/02.2024\u201301).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"The authors have read the STROBE Statement \u2013 checklist of items, and the manuscript was prepared and revised according to the STROBE Statement \u2013 checklist of item.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"STROBE Statement"}},{"value":"Unsolicited article; Externally peer reviewed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and Peer Review"}},{"value":"Single blind.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Peer-review model"}},{"value":"ESMO (ID\u2009=\u2009386744) & ASCO (ID\u2009=\u2009567724).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Corresponding Author's Membership in Professional Societies"}},{"value":"None.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}},{"value":"The authors declare no competing interests.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}